On July 31, Hims & Hers Health Inc. rose 6.62% in regular trading, trading at $27.67/share, with turnover of $80.88 million. The stock continued its recovery trajectory following the company's forceful rebuttal of a Federal Trade Commission lawsuit filed earlier this week.

The FTC sued Hims & Hers alleging the company shared users' health data with Meta Platforms and Snap without consent, and cited violations related to billing practices and subscription cancellation policies. The stock initially plunged over 12% on the news. However, the company issued a strong public statement declaring the charges baseless, emphasizing that the lawsuit ignores substantial evidence submitted during a nearly three-year investigation. Hims & Hers vowed to aggressively defend its position through legal action.

Market sentiment has continued to stabilize as investors digest the company's defiant posture and assess the lawsuit's potential impact ahead of its next earnings report scheduled for August 10.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)